跳至主要内容
临床试验/CTRI/2022/02/039948
CTRI/2022/02/039948尚未招募不适用

Comparative Clinical Study To Evaluate The Efficacy of Sarpagandha Ghana Vati and Kusmanda Rasayan After Virechana in Management of Vyanabala Vaishamya (Essential Hypertension)

All India Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年10月2日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
100
试验地点
1
主要终点
To evaluate and to compare the therapeutic effect of Sarpagandha Ghana Vati and Kushmanda Rasayana in the management of Vyanabala Vaishamya(Essential Hypertension).

研究概览

简要总结

Sarpagandha ghana vati is widely practice Ayurveda medicine in treatment of hypertension, as hypertension is raktaja vyadhi according to Ayurveda , Virechana(Medical purgation) followed by Rasayana like Sarpagnadha and other widely use drug Kusmanada Rasayan is taken to trail.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
21.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Systolic blood pressure >140 mm Hg Diastolic blood pressure >90 mm Hg Fit for Purgation therapy Willing to consent.

排除标准

  • Systolic >180 mm Hg, Diastolic >100 mm Hg Secondary Hypertension (CKD, Endocrine disorder, Type I , Type II diabetic ,pregnancy induced hypertension Age below 21 and above 70 Unfit for virechana Hypersensitivity to trail drug.

结局指标

主要结局

To evaluate and to compare the therapeutic effect of Sarpagandha Ghana Vati and Kushmanda Rasayana in the management of Vyanabala Vaishamya(Essential Hypertension).

时间窗: 106 days

次要结局

  • Change in quality of life SF-36 quality of life.(106 days)
  • Change in symptoms of Vyanabala Vaishamya (Essential Hypertension)(106 days)

研究者

申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验